NCT05696717Phase 3Active not recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-01Estimated

Enrollment · participants102Estimated

Source updated2025-09-05Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Symptomatic Neurogenic Orthostatic Hypotension; MSA - Multiple System Atrophy

Treatments or interventions studied

AmpreloxetineDrugAlso known as TD-9855
PlaceboDrug

Primary outcomes · main study measures

measure: Change in OHSA composite score at Week 8 during the double-blind RW period; description: Score change from baseline on the composite of Questions 1 - 6 of the Orthostatic Hypotension Symptom Assessment (OHSA).; timeFrame: 8-week randomized withdrawal period (Week 12 to Week 20)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history